United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
United Therapeutics Corp. (UTHR) PT Lowered to $223 at Jefferies
February 25, 2022 8:44 AM ESTJefferies analyst Eun Yang lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $223.00 (from $235.00) while maintaining a Buy rating.
The analyst commented, "Though disappointing, there are rational explanations for 4Q21 key products sales miss & another FDA approval delay for... More
United Therapeutics (UTHR) Misses Q4 EPS by 21c
February 24, 2022 6:10 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.51, $0.21 worse than the analyst estimate of $3.72. Revenue for the quarter came in at $415.2 million versus the consensus estimate of $427.62 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More